Размер шрифта
Цветовая схема
Изображения
Форма
Межсимвольный интервал
Межстрочный интервал
стандартные настройки
обычная версия сайта
закрыть
  • Вход
  • Регистрация
  • Помощь
Выбрать БД
Простой поискРасширенный поискИстория поисков
Главная / Результаты поиска

The prognostic impact of tumour NSD2 expression in advanced prostate cancer

Stangl-Kremser J., Lemberger U., Hassler M. R., Garstka N., Grubmüller B., Haitel A., Enikeev D. V., Gly'bochko P. V., Kramer G., Susani M., Shariat Sh.
Biomarkers
Vol.25, Issue3, P. 268-273
Опубликовано: 2020
Тип ресурса: Статья

DOI:10.1080/1354750X.2020.1734861

Аннотация:
Purpose: To assess the prognostic significance of the nuclear receptor binding SET protein 2 (NSD2), a co-activator of the NFkB-pathway, on tumour progression in patients with advanced prostate cancer (PCa). Methods: We retrospectively assessed NSD2 expression in 53 patients with metastatic and castration-resistant PCa. Immunohistochemical staining for NSD2 was carried out on specimen obtained from palliative resection of the prostate. Univariable and multivariable analyses were performed to assess the association between NSD2 expression and PCa progression. Results: Of the 53 patients, 41 had castration-resistant PCa and 48 men had metastases at time of tissue acquisition. NSD2 expression was increased in tumour specimen from 42 patients (79.2[%]). In univariable Cox regression analyses, NSD2 expression was associated with PSA progression, progression on imaging and overall survival (p = 0.04, respectively). In multivariable analyses, NSD2 expression did not retain its association with
Ключевые слова:
epigenetic; immunohistochemistry; NSD2; progress; Prostate cancer
carrier proteins and binding proteins; nuclear receptor binding SET protein 2; prostate specific antigen; transcription factor; unclassified drug; advanced cancer; aged; androgen deprivation therapy; Article; bone lesion; cancer growth; cancer prognosis; castration resistant prostate cancer; controlled study; epigenetics; follow up; Gleason score; human; human tissue; immunohistochemistry; major clinical study; male; metastasis; overall survival; prostate cancer cell line; protein expression; retrospective study; transurethral resection
Язык текста: Английский
ISSN: 1366-5804
Stangl-Kremser J.
Lemberger U.
Hassler M. R.
Garstka N.
Grubmüller B.
Haitel A.
Enikeev D. V. Dmitrij Viktorovich 1982-
Gly'bochko P. V. Petr Vitalyevich 1964-
Kramer G.
Susani M.
Shariat Sh. Sharokh 1973-
Стангл-Кремсер Й.
Лембергер У.
Хасслер М. Р.
Гарстка Н.
Грубмüллер Б.
Хаител А.
Еникеев Д. В. Дмитрий Викторович 1982-
Глыбочко П. В. Петр Витальевич 1964-
Крамер Г.
Сусани М.
Шариат Ш. Шарох 1973-
The prognostic impact of tumour NSD2 expression in advanced prostate cancer
Текст визуальный непосредственный
Biomarkers
Taylor & Francis Group
Vol.25, Issue3 P. 268-273
2020
Статья
epigenetic immunohistochemistry NSD2 progress Prostate cancer
carrier proteins and binding proteins nuclear receptor binding SET protein 2 prostate specific antigen transcription factor unclassified drug advanced cancer aged androgen deprivation therapy Article bone lesion cancer growth cancer prognosis castration resistant prostate cancer controlled study epigenetics follow up Gleason score human human tissue immunohistochemistry major clinical study male metastasis overall survival prostate cancer cell line protein expression retrospective study transurethral resection
Purpose: To assess the prognostic significance of the nuclear receptor binding SET protein 2 (NSD2), a co-activator of the NFkB-pathway, on tumour progression in patients with advanced prostate cancer (PCa). Methods: We retrospectively assessed NSD2 expression in 53 patients with metastatic and castration-resistant PCa. Immunohistochemical staining for NSD2 was carried out on specimen obtained from palliative resection of the prostate. Univariable and multivariable analyses were performed to assess the association between NSD2 expression and PCa progression. Results: Of the 53 patients, 41 had castration-resistant PCa and 48 men had metastases at time of tissue acquisition. NSD2 expression was increased in tumour specimen from 42 patients (79.2[%]). In univariable Cox regression analyses, NSD2 expression was associated with PSA progression, progression on imaging and overall survival (p = 0.04, respectively). In multivariable analyses, NSD2 expression did not retain its association with